The National Institute for Biological Standards and Control (NIBSC) has announced the appointment of a new director.
Director Dr Stephen Inglis has headed the institute for 14 years, but is now entering into retirement.
NIBSC have announced that Dr Christian K Schneider will replace Inglis, although he will not formally begin his duties in the organisation until January 2016.
Schneider is currently head of the medical division of the Danish Health and Medicines Authority.
The NIBSC is a global leader in the field of biological standardisation, and responsible for developing and producing over 90 per cent of the biological international standards currently in use globally.
Schneider brings a wealth of experience to the NIBSC, having previously enjoyed a prestigious career in medicine across mainland Europe.
His initial qualification in medicine was secured at the Max Planck Institute for Neurobiology, where Schneider also worked as a Postdoctoral Research Fellow.
Schneider later spent nearly a decade working at the Paul Ehrlich Institute in Germany, where he particularly specialised in microbiology.
Since October 2011, Schneider has worked with the Danish Health and Medicines Authority, initially as Senior Medical Officer, and latterly as the Medical Head of Division for Medicines Licensing and Availability.
Schneider possesses a particular extensive publication record, with dozens of his co-authored articles having appeared in a wide range of medical journals.
The new appointee has also taken up further prominent positions in addition to his day-to-day work.
Schneider is a former chair of the Committee for Advanced Therapies and continues to chair the Committee for Medicinal Products for Human Use (CHMP) Working Party on Similar Biological Medicinal Products at the European Medicines Agency.
He is also a former member of the CHMP.
Speaking about the new appointment, Dr Ian Hudson, Chief Executive of MHRA, was delighted to welcome Schneider, and looked forward to him filling his new post.
“I would like to take this opportunity to personally thank Stephen for his leadership of NIBSC, which has gone from strength to strength under his directorship, continuing to lead the world in biological standards, making a very significant contribution to public health throughout the world through its work on biological medicines,” Hudson reflected.
But Hudson was also keen to point out that although Schneider will be joining the institute in January of next year, the formal commencement of his directorship will not begin until 1st April, 2016.
Schneider will have many responsibilities in his new role once it becomes active, but perhaps one of the most notable is in relation to pandemic flu.
NIBSC is a key UK research centre in the field of pandemic flu, and also hosts the UK Stem Cell Bank.
The healthcare regulator, Monitor, has announced that the Deputy Chief Executive of Basildon Hospital, Adam Sewell-Jones, will join them as head of a team dedicated to ensuring NHS foundation trusts have effective support as they seek to improve their performance.
The regulator’s Provider Sustainability Directorate, which Mr Sewell-Jones is the first to head, aims to develop a pool of expertise to support foundation trusts. This includes bringing in-house much of the work currently done for the regulator by external suppliers in the fields of provider sustainability and solutions development.
At Basildon, Mr Sewell-Jones was instrumental in turning around a trust which had been subject to regulatory action for a number of years as part of the special measures programme. Basildon and Thurrock University Hospitals NHS Foundation Trust was removed from special measures in June 2014, following a successful inspection by the independent Care Quality Commission.
Previously, Mr Sewell-Jones worked for University College London Hospitals and Redbridge Healthcare NHS Trust. He was part of the NHS Top Leaders Programme 2010.
Leading clinician Dr Timothy Heymann has been appointed as a non-executive director of Monitor.
With a background in regulation, Dr Heymann is a key appointment for Monitor and he brings a wealth of expertise to the healthcare financial regulator.
As well as being the senior Consultant Physician and Gastroenterologist at Kingston Hospital, Dr Heymann also holds a post at Imperial College London as Reader in Health Management. Further expertise includes being a fellow of the Higher Education Academy and a host examiner of the Royal College of Physicians of London.
Dr Heymann has been a member of the Government’s Better Regulation Committee, and the Risk and Regulation Advisory Council. He has also been a non-executive director for NHS Direct.
Baroness Joan Hanham CBE, Chairman of Monitor, said: “I would like to warmly welcome Timothy Heymann to Monitor. His mix of extensive clinical experience and knowledge on regulation will be of real value to the decisions we take as we concentrate on making the health sector work for patients.”
Dr Timothy Heymann takes up his position as non-executive director on 16 February 2015. His appointment is for a period of three years.